BRAF and colorectal carcinoma: Cell lines with a KRAS/NRAS or BRAF mutation were associated with sensitivity to TAK-733 (p = 0.03), and even greater sensitivity was observed in 14 of 17 CRC cell lines that were KRAS/NRAS mutant and PIK3CA wild-type.